Fingerprint
Dive into the research topics of 'The transcription factor ZNF217 Is a prognostic biomarker and therapeutic target during breast cancer progression'. Together they form a unique fingerprint.- Sort by
- Weight
- Alphabetically
The transcription factor ZNF217 Is a prognostic biomarker and therapeutic target during breast cancer progression
Laurie E. Littlepage, Adam S. Adler, Hosein Kouros-Mehr, Guiqing Huang, Jonathan Chou, Sheryl R. Krig, Obi L. Griffi th, James E. Korkola, Kun Qu, Devon A. Lawson, Qing Xue, Mark D. Sternlicht, Gerrit J.P. Dijkgraaf, Paul Yaswen, Hope S. Rugo, Colleen A. Sweeney, Colin C. Collins, Joe W. Gray, Howard Y. Chang, Zena Werb
- Bursky Center for Human Immunology & Immunotherapy Programs (CHiiPs)
- Roy and Diana Vagelos Division of Biology & Biomedical Sciences (DBBS)
- Institute of Clinical and Translational Sciences (ICTS)
- Siteman Cancer Center
- Section of Bone Marrow Transplant & Leukemia
- Section of Stem Cell Biology
- DBBS - Molecular Cell Biology
- DBBS - Biomedical Informatics and Data Science
- DBBS - Cancer Biology
- Brain Tumor Center
- DBBS - Immunology
Research output: Contribution to journal › Article › peer-review
61
Scopus
citations